Lenis farmacevtika d.o.o. has obtained authorization under the new Act on Cannabis for Medical and Scientific Purposes to conduct activities involving cannabis for medical use.
The authorization enables Lenis to continue supplying the Slovenian market with GMP-grade medical cannabis products under the updated regulatory framework and in full compliance with applicable requirements.
This is not a new therapeutic or product area for Lenis. For years, we have been supplying the Slovenian market with GMP-grade medical cannabis products and were the first company to import such products into Slovenia.
Under the new legislation, activities involving cannabis for medical use, including importation, are subject to authorization by the Agency for Medicinal Products and Medical Devices of the Republic of Slovenia (JAZMP), the competent authority responsible for oversight in this area. The regulatory framework supports a controlled, traceable and safe supply system for patients, pharmacies, healthcare institutions and healthcare professionals.
Complex access challenges are where Lenis brings the most value. We are comfortable operating in highly regulated environments, where regulatory requirements, quality standards, international supply-chain constraints, traceability and patient needs must be aligned into practical, compliant solutions.
Obtaining this authorization confirms our continued commitment to ensuring safe, compliant and reliable access to medicines and medical products for patients in Slovenia.
